arrow_back Trending Legislation
Share share

Prohibiting Generic Drug Delays: Lower Prices, Greater Access

This act aims to prohibit pharmaceutical companies from paying other companies to delay the market entry of cheaper generic and biosimilar drugs. This means citizens can expect faster access to more affordable medications, potentially lowering healthcare costs and increasing the availability of important treatments.
Key points
Agreements where brand-name drug manufacturers pay generic drug manufacturers to delay market entry are prohibited.
The Federal Trade Commission (FTC) will enforce these rules, imposing significant financial penalties on companies that violate the law.
The goal is to increase competition in the pharmaceutical market, leading to lower drug prices for consumers.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
Protecting Consumer Access to Generic Drugs Act of 2021
Print number: HR 153
Sponsor: Rep. Rush, Bobby L. [D-IL-1]
Process start date: 2021-01-04
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch
Summary & Status

Key Questions about Prohibiting Generic Drug Delays: Lower Prices, Greater Access

A structured overview of the legislative process, official sources, status and civic context.

What is the official ID of this bill?

The official print number for this legislation is HR 153.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2021-01-04.

What are the main provisions?

Key points include:

  • Agreements where brand-name drug manufacturers pay generic drug manufacturers to delay market entry are prohibited.
  • The Federal Trade Commission (FTC) will enforce these rules, imposing significant financial penalties on companies that violate the law.
  • The goal is to increase competition in the pharmaceutical market, leading to lower drug prices for consumers.

What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Rush, Bobby L. [D-IL-1].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-27.

Analysis and Potential Impact of HR 153

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

CATEGORIES

Health Courts and Law Economy